DRG Market Assessment reports

DRG Epidemiology’s coverage of myelodysplastic syndromes comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

DRG Epidemiology’s coverage of myelodysplastic syndromes comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

DRG Epidemiology’s coverage of myelodysplastic syndromes comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias. Based on our survey results, the U.S. reimbursement environment…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia. Treatment goals…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stemcell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…

Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression to acute myeloid leukemia ( AML ). Management…

Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression to acute myeloid leukemia ( AML ). Management…

Myelodysplastic syndromes (MDS) consists of a group of hematological stem cell disorders that are heterogeneous in cause and manifestations but share the common features of aberrant hematopoiesis…

Myelodysplastic syndromes (MDS) consists of a group of disorders that are heterogeneous in cause and manifestations but share the common features of aberrant hematopoiesis and deteriorating…